Landscapes / Targets
PCSK9
10 drugs act on PCSK9, in 42 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs10
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Inclisirannot checked |
Small interfering RNA |
Approved | 27 Nov 2026soonPhase 4 trial completes | ||
| How it works | A short strand of RNA that switches off one gene | ||||
| Next date | 27 Nov 2026 · Phase 4 trial completes | ||||
| Also tested for | Hypercholesterolaemia, Acute Coronary Syndrome and 11 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Regeneron · Public REGN |
Approved | 29 Dec 2026Phase 2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 29 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Hypercholesterolemia | ||||
| Open drug page | |||||
Monoclonal antibody |
Amgen · Public AMGN |
Approved | 29 May 2027Phase 4 trial completes | ||
| How it works | An antibody | ||||
| Next date | 29 May 2027 · Phase 4 trial completes | ||||
| Also tested for | Cardiovascular Disease, Myocardial Infarction and 6 more | ||||
| Open drug page | |||||
Enlicitide Chloridenot checked |
— |
Merck & Co. · Public MRK |
Approved | 12 Oct 2027Phase 2 trial completes | |
| Next date | 12 Oct 2027 · Phase 2 trial completes | ||||
| Also tested for | Hypercholesterolemia, Arteriosclerosis and 4 more | ||||
| Open drug page | |||||
— |
Approved | 31 Jul 2028Phase 3 trial completes | |||
| Next date | 31 Jul 2028 · Phase 3 trial completes | ||||
| Also tested for | Familial Hypercholesterolemia - Heterozygous, Heterozygous Familial Hypercholesterolemia (HeFH) | ||||
| Open drug page | |||||
— |
Approved | — | |||
| Also tested for | Hypercholesterolemia, LDL-Cholesterol and 6 more | ||||
| Open drug page | |||||
— |
AstraZeneca · Public AZN |
Phase 3 | 4 Jan 2027Phase 3 trial completes | ||
| Next date | 4 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Cardiovascular Disease, Dyslipidaemia and 3 more | ||||
| Open drug page | |||||
— |
Phase 3 | 7 Oct 2027Phase 3 trial completes | |||
| Next date | 7 Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | Primary Hypercholesterolemia or Mixed Hyperlipidemia, Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Jun 2027Phase 2 trial completes | |||
| Next date | 30 Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Primary Hypercholesterolemia | ||||
| Open drug page | |||||
— |
Eli Lilly · Public LLY |
Phase 2 | Aug 2028Phase 2 trial completes | ||
| Next date | Aug 2028 · Phase 2 trial completes | ||||
| Also tested for | Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease and 3 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 8 of 10 drugs. The other 2 are marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026